Evidence map›Paper›PMID 33557789›Full record

ArticleBMC cancer2021

Post-treatment work patterns amongst survivors of lymphoma treated with high-dose chemotherapy with autologous stem-cell transplantation.

Kjersti Helene Hernæs, Knut B Smeland, Unn-Merete Fagerli, Cecilie E Kiserud

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 2 pooled it
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 syntheses or guidelines pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Kjersti Helene HernæsNorwegian Institute of Public Health, PO Box 222, Skøyen, N-0213, Oslo, Norway. KjerstiHelene.Hernaes@fhi.no.
Knut B SmelandNational Advisory Unit for Late Effects after Cancer Treatment, Oslo University Hospital, Radiumhospitalet, PO 4953, Nydalen, N-0424, Oslo, Norway.
Unn-Merete FagerliDepartment of Oncology, St. Olavs hospital HF, Postboks 3250 Torgarden, 7006, Trondheim, Norway.
Cecilie E KiserudNational Advisory Unit for Late Effects after Cancer Treatment, Oslo University Hospital, Radiumhospitalet, PO 4953, Nydalen, N-0424, Oslo, Norway.
Oslo University Hospital · NONorwegian Institute of Public Health · NONorwegian University of Science and Technology · NO

Funding

Helse Sør-Øst RHF 2011036Helse Sør-Øst RHF 2011098
6 · The paper itself

Abstract

backgroundThis study describes post-treatment work patterns in lymphoma survivors treated with high-dose chemotherapy with autologous stem-cell transplantation (HDT-ASCT). It aims to identify determinants for labour force participation and exclusion after HDT-ASCT.

methodsAll survivors treated with HDT-ASCT for lymphoma in Norway between 1995 and 2008, aged ≥18 years at HDT-ASCT and alive at survey in 2012-2013 were eligible. We divide survivors by current employment status (full-time, part-time and unemployed). Main outcomes are current employment status, work hours and work ability. Withdrawals are patients employed when diagnosed but not before HDT-ASCT.

resultsOf the 274 who completed the survey, 82% (N = 225) were included in the final analyses. Mean age at survey was 52 years, 39% were female, 85% were employed when diagnosed, 77% before HDT-ASCT and 69% at survey. Employment before HDT-ASCT corresponds with a higher probability of employment at survey for a given symptom burden. In the most extensive statistical model, it increases with 37.3 percentage points. Work hours amongst withdrawals plummet after HDT-ASCT while work ability shows a rebound effect. The potential economic gain from their re-enter into the work force equals 70% of the average annual wage in Norway in 2012.

conclusionsFor a given symptom burden, staying employed throughout diagnosis and treatment is associated with a higher probability of future employment. These results favour policies for labour force inclusion past diagnosis and treatment increasing cancer survivors' probability of future employment. However, we need more research on withdrawal mechanisms, and on policy measures that promote inclusion.

Indexed as

Quality of LifeAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCancer SurvivorsCombined Modality TherapyCross-Sectional StudiesEmploymentFemaleFollow-Up StudiesHematopoietic Stem Cell TransplantationHumansLymphomaMaleMiddle AgedPrognosisEmploymentHDT-ASCTLate effectsLymphomaWithdrawalWork ability

Identifiers

PMID33557789
PMCPMC7871541
OpenAlexW3127381364

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.